

Company name: Converge Bio

Website: www.converge-bio.com

CEO name: Dov Gertz

Select a CATEGORY: Bio Convergence

1. "AI Pharma" Drug Discovery, Quantum Computing

- **Executive Summary / Investment Rationale:**

Converge Bio empowers pharma and biotech with generative AI solutions built on their proprietary foundation models. Just two years since founding, the company has raised \$33M from Bessemer Venture Partners, the Gates Foundation, TLV Partners, and Vintage Investment Partners. They have assembled a 45-person team that represents one of the world's most talented frontier Bio-AI labs.

- **Core Technology:**

Converge's three solutions include:

1. ConvergeAB (antibody optimization)
2. ConvergeGEO (gene expression optimization)
3. ConvergeCELL (biomarker/target discovery)

These solutions combine generative and predictive AI trained on billions of biological data points. Operating zero-shot without target-specific fine-tuning, they deliver clinically meaningful improvements: up to 550× binding affinity gains, 7× protein yield increases, and superior biomarker prioritization versus standard methods.

- **Product Profile / Pipeline:**

Converge's platforms are commercially deployed with several biopharma partners. ConvergeAB has demonstrated superiority over state-of-the-art competitors including Cradle. ConvergeGEO outperforms GenScript, Twist, IDT, and ThermoFisher in protein yield. ConvergeCELL identified validated biomarkers across oncology, Crohn's, Parkinson's, and diabetes. All platforms are target-agnostic and immediately reusable across diverse drug programs.

- **Business Strategy:**

Converge generates near-term revenue through platform licensing, research collaborations and model development agreements with biotech and pharma partners. Long-term value is created by embedding Converge's AI into partners' R&D workflows across discovery, manufacturing, and clinical development, establishing recurring, program-level engagement and expanding platform applications as each product matures and new modalities are added.

- **What's Next?**

The team is scaling business development to deepen biotech and pharma partnerships with significant team growth occurring in the US and UK.